Sigma receptors (sigma-1 & sigma-2)

Sigma got its name by accident, and the accident is worth knowing because the name is still misleading people. In 1976, Martin and colleagues were mapping opioid pharmacology in dogs and identified three distinct drug syndromes, which they attributed to three receptors: mu, kappa and sigma, with the benzomorphan SKF-10,047 as the sigma prototype. That paper described the sigma syndrome as mydriasis, tachypnoea, tachycardia and mania, and speculated the effect might be dopaminergic ^[1].

For years sigma was filed as an opioid receptor subtype. In 1982 binding work showed that a portion of SKF-10,047 binding in guinea pig brain went to sites the strong opioid etorphine could not reach, that morphine-like drugs were poor inhibitors of those sites, and that non-opioid drugs including haloperidol, imipramine and propranolol were potent ones ^[2]. Sigma binding was not blocked by naloxone and had nothing structurally in common with opioid receptors, so the opioid label was dropped and the field was left with a genuinely orphan target.

It then went wrong a second time. Sigma was proposed as the receptor for phencyclidine, which turned out to be the NMDA channel instead, and the two were tangled together for most of the 1980s. A 1992 consensus proposal untied the knot and formally split the sigma binding sites into sigma-1 and sigma-2 on the basis of their opposite stereoselectivity for benzomorphans and their different apparent sizes ^[3]. So a subtype division existed for twenty-five years before anybody knew what either protein was.

That history explains a habit worth resisting. When a compound page says a molecule is a sigma-1 ligand, that is a statement about binding, not about a transmitter system. There is no sigma nerve, no sigma synapse and no sigma release event to modulate.

Sigma-1 was purified and cloned in 1996 from guinea pig liver using radiolabelled pentazocine, and the sequence came back with a surprise: no homology to any known mammalian protein. Its closest relatives were fungal enzymes involved in sterol synthesis, and the messenger RNA was densest in steroid-producing tissues ^[4]. A 223-amino-acid protein with no relatives in its own proteome is unusual enough on its own.

The functional reframing came in 2007, when sigma-1 was shown to be a ligand-operated chaperone at the ER-mitochondrion interface, sensing ER calcium and regulating calcium flow through IP3 receptors into mitochondria. In the same work, raising sigma-1 levels made cells more resistant to ER stress and lowering them made cells more prone to apoptosis ^[5]. That turned a mysterious binding site into a piece of the cell's stress-response machinery.

Structure filled in the rest. The human sigma-1 receptor was crystallised in 2016 and looked like nothing else in the human proteome: a trimer with a single transmembrane helix per protomer, a flat hydrophobic face pressed against the cytosolic side of the ER membrane, and a deep ligand pocket buried in a cupin-like beta-barrel. Two chemically dissimilar ligands bound in almost the same position, which says something about how promiscuous that pocket is ^[8]. In 2018 the same group solved it with the antagonists haloperidol and NE-100 and with the agonist pentazocine, and found that ligand binding is a multistep process rate-limited by receptor conformational change rather than by diffusion ^[9]. That is one reason sigma ligands often show slow, unusual binding kinetics.

More recent work argues the protein's real currency is membrane organisation. Sigma-1 binds cholesterol through a motif in its transmembrane region, clusters into cholesterol-enriched microdomains that are locally thicker than the surrounding ER membrane, and agonists disperse those clusters ^[11]. If that is right, a sigma-1 agonist is not switching on a pathway so much as reorganising a patch of membrane and everything sitting in it. Sigma-1 has also been described as behaving like a small heat shock protein and exists as monomers, dimers, tetramers and higher oligomers, with the oligomeric state itself likely shaping the pharmacology ^[10].

The two subtypes were separated by pharmacology long before anyone knew what they were, and when the identities finally arrived they turned out to be unrelated proteins that simply happen to bind an overlapping set of small molecules ^[3].

Sigma-2 took the longest. Despite the name, it eluded cloning for four decades, and its molecular identity was only established in 2017, when it was purified from tissue by a chemical biology approach and shown to be TMEM97, an ER transmembrane protein that regulates the sterol transporter NPC1 ^[16]. That is 41 years after the sigma name was coined and 25 years after the subtype split was proposed. It is worth saying plainly: for most of the period during which the phrase sigma-2 receptor appeared in the literature, nobody knew what protein was being discussed.

There was also a false identification along the way. Sigma-2 had been reported as identical to PGRMC1, a progesterone receptor membrane component, and that claim propagated for several years. In 2015 a careful comparison showed that the sigma-2 binding site and PGRMC1 are different binding sites derived from independent genes, which removed a widely cited but incorrect identity ^[17]. Anything written about sigma-2 before roughly 2015 should be read with that in mind.

So: sigma-1 is about calcium, chaperoning and neuroplasticity. Sigma-2 and TMEM97 are about cholesterol and lipid handling, autophagy and cell proliferation, which is why the sigma-2 literature runs through cancer imaging and neurodegeneration rather than through mood ^[16][19]. Sigma-2 ligands also produce long-lasting relief of mechanical hypersensitivity in a mouse nerve injury model, which is the clearest behavioural handle on the target so far ^[18].

There is no G protein here and no ion pore, so the output has to be described differently from every other page in this set. Sigma-1 acts by holding onto other proteins and changing how they behave, and it does that in at least three places.

At the MAM. Ligand binding or a drop in ER calcium separates sigma-1 from BiP, and free sigma-1 stabilises IP3 receptor type 3 so the calcium signal into mitochondria lasts longer. Mitochondrial ATP production depends on that calcium arriving, which is the link between a sigma-1 ligand and cellular energetics ^[5].

At the plasma membrane and wider ER. Under sustained stimulation or chronic stress, sigma-1 translocates out of the MAM and associates with ion channels, receptors and kinases elsewhere in the cell ^[6]. The reviewed pattern across many systems is consistent and slightly counter-intuitive: sigma-1 agonists inhibit voltage-gated channels, including calcium, potassium, sodium and chloride channels, while potentiating ligand-gated ones such as NMDA and IP3 receptors, and antagonists block both effects ^[7].

Through BDNF. Sigma-1 agonists increase the secretion of mature BDNF from its precursor proBDNF, an effect attributed to chaperone activity inside the ER rather than to receptor signalling in the usual sense ^[12]. This is the mechanistic bridge that connects sigma-1 to antidepressant and neurite-growth claims, and it is a processing effect, not a transmitter effect. See BDNF and neuroplasticity for what that growth factor does and does not do.

One awkward consequence of having no canonical output: agonist and antagonist are defined operationally here, from functional assays, rather than from a signalling readout everyone agrees on. A compound is called an agonist because it reproduces the effects of pentazocine or PRE-084 in a given model and an antagonist because it blocks them ^[7][10]. That works well enough within a laboratory and travels badly between them, and it is a real reason the sigma literature contains apparent contradictions.

The single most practical fact about sigma-1 is that its binding pocket is large, hydrophobic and forgiving, and a startling number of ordinary drugs fit into it. That is a warning as much as an observation: finding sigma affinity in a binding panel is common, and it tells you very little on its own about whether the drug's effects run through sigma.

The strongest human evidence in the class belongs to Fluvoxamine. It has the highest sigma-1 affinity of the SSRIs at a reported Ki of 36 nM, against 1,893 nM for paroxetine, and a positron emission tomography study in fifteen healthy volunteers showed dose-dependent binding to sigma-1 receptors across the brain after a single ordinary oral dose, while paroxetine showed none ^[22]. That is target engagement demonstrated in living people, which almost nothing else on this page can claim.

The neurosteroids are the reason the field keeps circling back to an endogenous ligand. Sigma-1 binding sites were known to interact with steroids from the cloning paper onward ^[4], and DHEA is routinely described as an endogenous sigma-1 agonist ^[12], with Progesterone usually behaving as an antagonist. Whether any of them is the physiological ligand has never been established, which is covered further below.

The reason sigma-1 shows up so often in nootropic discussion is that it reads as a plasticity and resilience amplifier rather than a driver. It does not fire a pathway on its own; it stabilises machinery a stressed cell needs, from IP3-driven calcium signalling to the secretion of mature BDNF ^[6][12]. Effects in animal models are frequently larger when the tissue is already damaged than when it is healthy, which fits a chaperone and fits poorly with the idea of a receptor whose job is to be stimulated.

The strongest evidence that the protein genuinely matters in humans is genetic rather than pharmacological. A homozygous mutation in SIGMAR1 causes an autosomal recessive juvenile amyotrophic lateral sclerosis, and the mutant protein mislocalises in motor neuron-like cells and leaves them less able to survive ER stress ^[14]. A separate mutation in the untranslated region of the same gene, which raises expression rather than breaking the protein, segregates with frontotemporal lobar degeneration with motor neuron disease in a pedigree, and carriers show a distinctive pathology ^[15]. Losing sigma-1 and over-expressing it both cause neurological disease, which is a strong argument that the protein is load-bearing.

That said, the loss-of-function evidence has a large caveat that rarely gets quoted. Sigma-1 knockout mice are viable, fertile, and show no overt phenotype compared with their wild-type littermates, with the main detectable change being a reduced hypermotility response to the sigma agonist SKF-10,047 ^[13]. A protein that a mouse can do without entirely is unlikely to be the master switch some write-ups imply.

For nootropic reading, the practical translation is narrow. When an entry mentions sigma-1, read it as supports calcium signalling, ER stress handling and BDNF-linked plasticity, usually in a protective and self-limiting way, and read a claimed sigma-1 mechanism as a hypothesis about why something might work rather than as a demonstration that it does. For where this sits among the better-characterised systems, see neurotransmitters 101, and for the receptor family sigma was originally and wrongly filed under, see opioid receptors.

There is no agreed natural ligand. This is the largest gap and it is rarely stated. Three candidate classes exist and none is accepted. Neurosteroids bind, and the cloning paper already noted the sterol connection ^[4][12]. DMT was proposed as an endogenous sigma-1 regulator in 2009 on the strength of binding, sodium channel inhibition and a behavioural difference between wild-type and knockout mice ^[20]; that report has not been independently established as describing a physiological relationship, and endogenous DMT concentrations in mammalian brain are low. Choline was proposed in 2019 as an intracellular messenger acting through sigma-1 to shape IP3-evoked calcium signals ^[21], which is a different kind of proposal entirely. A receptor family with no settled endogenous ligand after fifty years is not in the same evidential position as dopamine or GABA.

Agonist and antagonist are not defined the way they are elsewhere. Without a G protein or a channel there is no canonical readout, so the labels come from functional models and do not always transfer between them ^[7][10]. Whether sigma-1's real action is chaperoning individual client proteins or reorganising cholesterol-rich membrane microdomains is also open, and the second account would reframe what agonism means here ^[11].

Sigma-2 is early. Its identity as TMEM97 is only eight years old at the time of writing ^[16], it replaced an incorrect identification that had circulated for years ^[17], there is no experimental structure, and whether receptor is even the right word for a cholesterol-handling ER protein is a fair question. The pain result in mice is genuinely interesting and genuinely preliminary ^[18].

The human clinical record is thin and mostly negative. Sigma-1 has been an attractive target for three decades and has not yet produced an approved drug for any indication. The table below is the published trial record for the leading candidates, stated as the trials themselves reported it. The sigma-2 programme is younger: the completed phase 2 crossover study of zervimesine (CT1812) in Alzheimer's disease reported cerebrospinal fluid biomarker changes and quantitative EEG effects, which is target engagement and pathway evidence rather than a cognitive endpoint ^[28].

None of that makes sigma uninteresting. It makes it early. A protein with no relatives, no known natural ligand, a structure unlike anything else in the human proteome, and disease-causing mutations in both directions is a genuinely open scientific question. It is simply not, today, a lever anyone knows how to pull reliably. For the general problem of reading a mechanism claim that has not yet produced an outcome, see nootropics.